Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
6990-06-3
Molecular formula
C31H48O6
Molecular weight
516.7 g/mol
Drug class
Steroidal-structure antibioticelongation factor G (EF-G) inhibitor
Mechanism of action
Binds bacterial elongation factor G (EF-G) and prevents its release from the ribosome after translocation, inhibiting protein synthesis and bacterial growth.
Indications / reported uses
Topical treatment of localised bacterial skin infections caused by susceptible Staphylococcus aureus, including impetigo and infected dermatitis, with authorised topical formulations
Systemic treatment of serious susceptible staphylococcal infections in selected jurisdictions and formulations; topical and systemic indications are not interchangeable
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Fusidic Acid Environmental Risk Assessment (ERA) (the Fusidic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.